SAGIMET BIOSCIENCES IN

5,5400

27-ноября-24 16:45:00

15 мин. задержка

Акции

+0,3700

+7,16%

Сегодняшний диапазон

5,1900 - 5,6470

ISIN

N/A

Источник

NASDAQ

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

18 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

14 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

07 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

29 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

11 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

01 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 окт 2024 00:05:00 Источник Nasdaq GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

04 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

14 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

01 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

10 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

06 июн 2024 05:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

16 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

07 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

06 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.